1. merck sharp & dohme b.v
  2. flugen inc
  3. gensight biologics
  4. Search the database for deliberate release of GM medicinal products

Search the database for deliberate release of GM medicinal products

Displaying 1 - 1 of 1
EU record number Title Company / Sponsor Treated organism Genetic modification
Only notified under the "contained use" procedure. Dossier submitted on 21/02/2018. Efficacy and safety of bilateral intravitreal injection of GS010: a randomized, double-masked, placebo-controlled trial in subjects affected with G11778A ND4 leber hereditary optic neuropathy for up to one year. GenSight Biologics Humans human wild-type MT-NDA (mitochondrial NADH Dehydrogenase 4)